Clinical Trials Logo

Macular Degeneration clinical trials

View clinical trials related to Macular Degeneration.

Filter by:

NCT ID: NCT04480463 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

Start date: August 13, 2020
Phase: Phase 3
Study type: Interventional

Age-related macular degeneration (AMD) is a leading cause of vision loss in adults. Abnormal blood vessels grow under the macula at the back of the eye, and also leak blood and fluid, which damages and scars the macula, affecting vision. The current standard of care for patients with neovascular (exudative / wet) AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy, which prevents or slows down the growth of the abnormal blood vessels. SCD411 is being developed as a biosimilar to the reference product Eylea® (aflibercept), an anti-VEGF drug. The study aims to prove equivalence of SCD411 to Eylea in adults with wet AMD, and will look at safety, tolerance, effectiveness, immune response and the movement of the drug through the body.

NCT ID: NCT04455399 Completed - Clinical trials for Diabetic Macular Edema

Time Efficiency Comparison of Two IntraVitreal Injection Techniques

TIVI
Start date: November 9, 2020
Phase: N/A
Study type: Interventional

Prospective, single-center, randomized, clinical trial (RCT) comparing the time efficiency and safety of a single-use intravitreal injection (IVI) guide versus a traditional technique using a dual blade speculum among patients undergoing IVI for various indications.

NCT ID: NCT04450329 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Start date: June 23, 2020
Phase: Phase 3
Study type: Interventional

This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy, safety, Pharmacokinetics (PK), and immunogenicity of SB15 compared to Eylea® in subjects with neovascular AMD.

NCT ID: NCT04435366 Completed - Clinical trials for Macular Degeneration

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Start date: June 22, 2020
Phase: Phase 3
Study type: Interventional

The objectives of this study are to evaluate the safety and efficacy of Zimura (avacincaptad pegol) intravitreal administration in patients with geographic atrophy secondary to age-related macular degeneration (AMD)

NCT ID: NCT04422899 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

Effect of Intravitreally Administered AIV007 in Subjects With nAMD

Start date: August 28, 2020
Phase: Phase 1
Study type: Interventional

To determine safety, pharmacokinetics, and duration of effect of intravitreally administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration

NCT ID: NCT04395859 Completed - Clinical trials for Diabetic Macular Edema

Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents

COVIDIV
Start date: May 27, 2020
Phase:
Study type: Observational

In patients treated for exudative age-related macular degeneration (AMD), diabetes, retinal venous occlusion (OVR), or other conditions causing macular edema, treatments with anti-angiogenic intravitreal injections (IVT) are widely used both for their anti-angiogenic action. Patients often have injections for many years, sometimes monthly or every 2 months. The discontinuation of treatment with repeated injections of anti-angiogenic agents, linked to the COVID-19 coronavirus pandemic will potentially impact the visual acuity, the ophthalmological state and the quality of life of the patients concerned, therefore it is relevant to analyze the consequences the breakdown of usual care in this population.

NCT ID: NCT04370379 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients

Start date: May 28, 2020
Phase: Phase 1
Study type: Interventional

This study is designed for multi-center, open-label, randomized, dose escalation phase I trial to evaluate the safety and tolerability of a multiple dose intravitreal injection of IBI302 in neovascular AMD patients.

NCT ID: NCT04349254 Completed - Clinical trials for Dry Age-related Macular Degeneration

Observational Study of Vision Improvement in Late Stage Dry AMD Patients

Start date: August 14, 2020
Phase:
Study type: Observational

The purpose of this study is to assess the vision improvement achieved by patients with late stage dry age-related macular degeneration who received corneal treatments by a low vision aid device.

NCT ID: NCT04331730 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD

PHTHALO-205
Start date: January 28, 2020
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).

NCT ID: NCT04304755 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)

Z-AMD
Start date: October 25, 2021
Phase: Phase 2
Study type: Interventional

A pilot study of zoledronic acid as adjuvant therapy to standard anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD).